Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Terflavoxate is a novel, orally active, semisynthetic statin microtubule inhibitor commonly used in combination with capecitabine. Terflavoxate is used in cancer research.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 195.00 | |
5 mg | In stock | $ 440.00 | |
10 mg | In stock | $ 648.00 | |
25 mg | In stock | $ 987.00 | |
50 mg | In stock | $ 1,390.00 | |
100 mg | In stock | $ 1,870.00 | |
500 mg | In stock | $ 3,730.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 496.00 |
Description | Terflavoxate is a novel, orally active, semisynthetic statin microtubule inhibitor commonly used in combination with capecitabine. Terflavoxate is used in cancer research. |
In vitro | Terflavoxate showed affinity for bladder (and brain) muscarinic receptors at micromolar level. Terflavoxate could inhibiting the two components of K(+)-induced contractions. Present results suggest that Ca(++)-antagonistic effects are mainly responsible for terflavoxate smooth muscle relaxant properties.[1] |
Molecular Weight | 419.51 |
Formula | C26H29NO4 |
CAS No. | 86433-40-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.19 mg/mL (10 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Terflavoxate 86433-40-1 Cytoskeletal Signaling Microtubule Associated inhibitor inhibit